{"filing":{"accession_number":"0001651625-26-000020","cik":"0001651625","ticker":"ACIU","company_name":"AC Immune SA","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"aciu-20260923x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651625/000165162526000020/aciu-20260923x6k.htm"},"events":[{"id":34461,"run_id":31706,"accession_number":"0001651625-26-000020","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This is a press release announcing positive clinical trial results for ACI-7104 in the VacSYn Phase 2 trial. While not a financial earnings release, it discloses material clinical trial outcomes (all primary endpoints met, 100% immunogenicity response rate, CSF antibody penetration, target engagement signals) that would significantly affect investor assessment of the company's lead program and development trajectory. The disclosure of clinical milestones and regulatory pathway discussions is material to a biopharmaceutical company's valuation and prospects.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38186,"accession_number":"0001651625-26-000020","item_number":"EX-99.1","item_title":"aciu-20260923xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a press release announcing positive clinical trial results for ACI-7104 in the VacSYn Phase 2 trial. While not a financial earnings release, it discloses material clinical trial outcomes (all primary endpoints met, 100% immunogenicity response rate, CSF antibody penetration, target engagement signals) that would significantly affect investor assessment of the company's lead program and development trajectory. The disclosure of clinical milestones and regulatory pathway discussions is material to a biopharmaceutical company's valuation and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:00:58.158740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38186,"accession_number":"0001651625-26-000020","item_number":"EX-99.1","item_title":"aciu-20260923xex99d1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a press release announcing positive clinical trial results for ACI-7104 in the VacSYn Phase 2 trial. While not a financial earnings release, it discloses material clinical trial outcomes (all primary endpoints met, 100% immunogenicity response rate, CSF antibody penetration, target engagement signals) that would significantly affect investor assessment of the company's lead program and development trajectory. The disclosure of clinical milestones and regulatory pathway discussions is material to a biopharmaceutical company's valuation and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:00:58.158740+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-09-23"}]}